San Diego, CA

IPO April 2021 (NASDAQ: RPHM)

Reneo, a RiverVest-founded company, is a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Reneo’s goal is to improve daily function and quality of life of patients suffering from these diseases.


© Copyright RiverVest® All Rights Reserved.